财务数据和关键指标变化 - 公司2023年第二季度收入为1.088亿美元,同比增长4%,其中美国永久植入手术量同比增长8% [32] - 公司2023年第二季度毛利率为68.4%,同比下降1.4个百分点 [34] - 公司2023年第二季度非GAAP调整后EBITDA亏损310万美元,同比亏损减少140万美元 [36] - 公司2023年6月30日现金、现金等价物和短期投资总额为3.299亿美元,较上季度减少1180万美元 [36] 各条业务线数据和关键指标变化 - 公司PDN适应症销售额为1900万美元,同比增长73% [32] - PDN适应症占公司全球永久植入手术量的18% [32] - PDN试植手术量占公司美国总试植手术量的23%,较上年同期增加9个百分点 [18] 各个市场数据和关键指标变化 - 公司美国收入同比增长4% [33] - 公司国际收入同比增长5%,按固定汇率计算增长4% [33] 公司战略和发展方向及行业竞争 - 公司将继续拓展适应症,如正在进行的PDN感觉研究 [26] - 公司将推出HFX iQ等新产品线延伸,并支持强大的研发管线 [12][17] - 公司将考虑通过战略机会补充产品组合 [12] - 公司将继续扩大在PDN和非手术性腰痛等未开发市场的渗透 [12][13] - 公司将专注于提高商业执行力,包括调整销售团队组织架构、提高销售代表绩效等 [12][13] - 公司将继续扩大在Costa Rica的制造基地,提高运营效率和精简内部流程 [12] - 行业内其他主要参与者中有一家在第二季度报告了持平或略有下降的美国业绩 [15][44] 管理层对经营环境和未来前景的评论 - 公司认为市场正在复苏,但复苏不会是线性的,而是会有起起伏伏 [15][44][45] - 公司相信长期来看,市场将恢复到历史6%-9%的增长水平 [82] - 公司对2023年下半年的指引较之前保守,主要是由于市场复苏的非线性特点以及内部商业执行力的调整需要一定时间 [44][45][49] - 公司对长期前景充满信心,相信可以通过改善商业执行力、扩大制造基地、推出新产品等措施实现收入增长、利润改善和运营杠杆提升 [29][38] 问答环节重要的提问和回答 问题1 **Anthony Petrone 提问** 提问了公司第三季度和第四季度的隐含指引,以及销售团队重组对下半年业绩的影响 [48][49] **Kevin Thornal 回答** 回答了销售团队重组的目的和预期影响,以及第三季度和第四季度指引的考虑因素 [50][51][52] 问题2 **Simran Kaur 提问** 询问了第三季度指引大幅下滑的原因 [55][56] **Kevin Thornal 和 Rod MacLeod 回答** 解释了第三季度指引下滑的原因,包括季节性因素以及内部商业执行力调整的短期影响 [57][58][60] 问题3 **Nathan Treybeck 提问** 询问了公司未来3年内拓展新适应症和新技术的计划,以及是否会考虑通过股权融资进行并购 [62][63] **Kevin Thornal 和 Rod MacLeod 回答** 介绍了公司正在进行的PDN感觉研究等新适应症开发计划,并表示会考虑通过并购等方式适当拓展产品组合,但具体时间和方式还需视情况而定 [63][64][68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or org ...

1Q 2023 Earnings Call Presentation A P RI L 2 6 , 2 0 2 3 Forward-Looking Statements 2 Management uses certain non-GAAP financial measures, most specifically Adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the company's operating performance period over period, analyze the underlying business trends, assess performance relative to competitors and establish operational objectives. • Stock-based compensation expense – The company excludes non-cash costs related to the company's ...

Kevin Thornal Thanks, Larry. Operator Your next question comes from the line of Bill Plovanic with Canaccord. Bill Plovanic Great. Thanks for taking my question and I echo LarryÂ's comments for both Keith and Kevin. Just my question is really going to be more on market share. As we look at this, Keith and Rod just on the numbers. It looks like the U.S. Spinal Cord business was flat, which is a great improvement when you strip out the PDN, but I am just curious when you can -- your commentary that you think ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Iden ...

Keith Grossman Okay. Thanks, Joanne. Why donÂ't I take the PDN Salesforce build and the search and IÂ'll let Rod take the CAGR question. So, the PDN referral Salesforce build is sort of an ongoing process. We tend to go in tranches once or a couple times a year and I – in the past, and I think this year, it'll be more of a continual building. So weÂ've come into this year with a referral sales team of little more than 50 individuals, I think, will probably exit this year with something closer to 80 to 90. A ...

Nevro Corporation (NYSE:NVRO) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Participants Simran Kaur - Piper Sandler & Co. Joanne Wuensch - Citi Devin Geiman - Nephron Research David Rescott - Truist Securities Brandon Vazquez - William Blair & Company Nathan Treybeck - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. David ...

3Q 2022 Earnings Presentation N O VE M BER 2 , 2 0 2 2 Dania Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our full year 2022 financial guidance; our belief that we will continue to see a gradual overall trend of SCS market recovery, which we expect to c ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | From Recovery to | | | | | | | | Renewed Growth | | | | | | | | Canaccord Genuity Annual Growth Conference | | | | | | | | R O D M a c LEOD C H I E F F I N A N C I A L O F F I C E R A UG US T 1 0 , 2 0 2 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Forward-Loo ...